Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

Contract Win

10 Jun 2025 07:00

RNS Number : 0211M
GenIP PLC
10 June 2025
 

 

 

10 June 2025 

 

GenIP Plc

("GenIP" or the "Company")

 

Contract Win

 

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce its expansion into the Republic of Chile through an engagement for 30 analytical assessment orders from a leading research institution.

 

This order increases the total value of Invention Evaluator orders received by GenIP since its IPO in October 2024 to over $850,000[1].

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"I am delighted to announce another new international contract with a leading research university, marking GenIP's first entry into the Chilean market. The institution has purchased 30 Invention Evaluator assessments, to support technology commercialisation decisions across its research portfolio. This milestone strengthens GenIP's growing footprint in Latin America and underscores global demand for its GenAI-enabled services.

 

"GenIP's global expansion is underpinned by a healthy balance sheet that allows the Company to capitalise on opportunities as they arise. As outlined in our audited results, the reported Operating Loss of $888,545 included $358,924 of share-based payments relating to the IPO that are not expected to recur. Customers typically pay in advance for Invention Evaluator report orders, providing the Company with operating cash flow and future revenue visibility, with revenue recognised upon completion and delivery of the report to the client. These factors help maintain the Company's strong financial position."

 

 

 

For further information regarding GenIP, please visit https://genip.ai/, or contact:

 

GenIP Plc

Melissa Cruz, CEO 

Via Redchurch Communications

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

 

 

Tel: +44 (0) 20 7628 3396

 

Novum Securities Limited (Broker) 

Jon Belliss

Tel: +44 (0)20 7399 9425

JBelliss@novumsecurities.com

 

 

Redchurch Communications (Financial PR)

John Casey

 

 

genip@weareredchurch.com

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary platform-based services:

1. Invention Evaluator: Provides bespoke research reports that assess the market potential of new technological innovations and discoveries using AI-driven proprietary software; and

 

2. Vortechs: which is an executive recruitment platform that through advanced machine learning algorithms and natural language processing technologies assists in matching technology organisations with experienced executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help organisations to evaluate and commercialise their technological innovations. 

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To achieve this, the Company has established three strategic pillars:

 

Organically grow Invention Evaluator and Vortechs' revenue through institutional and corporate connections as well as increase client pipeline through marketing, advertising and social media spend.

Expand the Generative AI service offerings within Invention Evaluator and Vortechs' to reach new customers and improve margins.

Bolt-on acquisitions of additional Generative AI services that are helpful to our clients and have demonstrated initial market traction. 

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-


[1] Orders are treated as pre-payments with revenue recognised upon report production by GenIP and delivery to the client. Typically, pre-payments are utilised approximately 50% within the first 12 months and the balance over the following 12-18 months.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTUKRRRVRUNRAR
Date   Source Headline
4th May 20181:45 pmRNSFinal Results
19th Apr 20187:00 amRNSUK Investor Show
1st Mar 20187:00 amRNSUpdate on Lucyd Blockchain Token Generation Event
14th Feb 20187:00 amRNSPrivate Placement for Belluscura to raise US$1.33m
24th Jan 20187:00 amRNSHolding(s) in Company
22nd Jan 20187:00 amRNSUpdate on Lucyd Blockchain Token Generation Event
18th Dec 20174:14 pmRNSHolding(s) in Company
1st Dec 201710:14 amRNSUpdate re. Belluscura IPO
16th Nov 20178:00 amRNSUpdate re. Belluscura IPO
30th Oct 20177:00 amRNSAcquisition of a Patented AI Valet System
28th Sep 20177:00 amRNSPortfolio Company to Raise Funds via a Token Sale
22nd Sep 20177:00 amRNSInvestor Briefing
31st Jul 20177:00 amRNSHalf-year Report
31st May 201711:18 amRNSResult of AGM
31st May 20177:00 amRNSAcquisition of New Gesture Recognition Technology
9th May 20175:13 pmRNSFinal Results
8th May 20179:11 amRNSNotice of AGM
3rd May 20177:00 amRNSPrivate Placement for Belluscura Ltd
2nd May 20179:31 amRNSApp to Search Global University IP
25th Apr 20177:00 amRNSBelluscura acquires Nanotether Discovery Science
20th Mar 20179:11 amRNSHolding(s) in Company
16th Mar 20179:30 amRNSHolding(s) in Company
10th Mar 20179:31 amRNSExercise of Warrants
3rd Mar 20177:00 amRNSBelluscura Launches Passport Medical Device in US
2nd Mar 20177:00 amRNSBelluscura Ltd Launches Slyde in EU
1st Mar 20177:00 amRNSBelluscura Ltd Launches Wire CaddyT In USA
28th Feb 20177:00 amRNSLicense and Development Agreement
15th Feb 20177:00 amRNSAppointment of Joint Broker
2nd Feb 20179:55 amRNSHolding(s) in Company
1st Feb 20175:25 pmRNSHolding(s) in Company
31st Jan 20174:26 pmRNSTotal Voting Rights and Holding in Company
26th Jan 20173:00 pmRNSResults of proposed placing to raise £2.4m
26th Jan 20177:00 amRNSProposed placing
12th Jan 20177:00 amRNSNotice of Allowance for Energy Harvester Patent
4th Jan 20177:00 amRNSSuccessful Production and Testing of µSaltTM
28th Dec 20167:00 amRNSOut-licence & Strategic Alliance with Wecast
9th Nov 20167:00 amRNSDirectorate Change
31st Oct 20167:00 amRNSStrategic Alliance with Bajainnova SAPI de CV
28th Oct 20167:00 amRNSNotice of Allowance for 2nd Crackle-baked Patent
25th Oct 20167:00 amRNSPrivate Placement for Belluscura Ltd
7th Oct 20164:28 pmRNSHolding(s) in Company
15th Sep 20167:00 amRNSAcquisition of Medical Device Licence
31st Aug 20167:00 amRNSHalf-year Report
30th Jun 20167:30 amRNSGrant of Options
17th Jun 20167:00 amRNSPrivate Placement for Belluscura Ltd
6th Jun 201611:44 amRNSAcquisition of salt reduction technology patent
27th May 20162:47 pmRNSResult of AGM
4th May 20167:00 amRNSPosting of Annual Report and Notice of AGM
29th Apr 20167:00 amRNSFinal Results
28th Apr 20167:00 amRNSAcquisition and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.